Mitsubishi UFJ Asset Management Co. Ltd. Acquires 685,111 Shares of Pfizer Inc. $PFE

Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.0% during the 4th quarter, HoldingsChannel reports. The fund owned 12,081,382 shares of the biopharmaceutical company’s stock after buying an additional 685,111 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Pfizer were worth $304,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Pfizer in the third quarter worth $3,019,000. Money Concepts Capital Corp increased its stake in Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Kepler Cheuvreux Suisse SA bought a new position in Pfizer in the 3rd quarter worth about $16,613,000. Penn Davis Mcfarland Inc. raised its holdings in shares of Pfizer by 50.9% in the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after acquiring an additional 57,777 shares in the last quarter. Finally, Callahan Advisors LLC boosted its position in shares of Pfizer by 6.5% during the 3rd quarter. Callahan Advisors LLC now owns 713,797 shares of the biopharmaceutical company’s stock valued at $18,188,000 after acquiring an additional 43,454 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 0.5%

Shares of PFE opened at $26.42 on Wednesday. Pfizer Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $28.75. The firm has a market cap of $150.24 billion, a price-to-earnings ratio of 19.43 and a beta of 0.35. The firm has a 50 day moving average price of $27.17 and a 200-day moving average price of $26.13. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.5%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s payout ratio is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q1 results beat expectations: Pfizer reported $14.45B in revenue and $0.75 EPS, topping Street estimates as growth from recently launched and acquired products (notably Eliquis and cancer drugs) offset declines in COVID sales. Pfizer beats Q1 profit estimates on strong demand for blood thinner Eliquis (Reuters)
• Positive Sentiment: Pipeline and M&A support longer-term growth: Management highlighted pipeline progress and the strategic Metsera acquisition (obesity) as key to offsetting legacy declines and to drive post‑2028 growth. Pfizer tops Wall Street estimates, reaffirms outlook as newer products show growth (CNBC)
• Positive Sentiment: Legal and patent developments extend revenue visibility: A patent settlement around Vyndamax and recent favorable rulings (including COVID‑vaccine related wins) were cited as reshaping the company’s post‑2028 revenue outlook. Pfizer Says Vyndamax Drug Patent Settlement Reshapes Post-2028 Revenue View (Benzinga)
• Positive Sentiment: New FDA approval: Pfizer (with Arvinas) won approval for VEPPANU, a first‑of‑its‑kind therapy for ESR1‑mutated advanced breast cancer, adding a near‑term commercial product. Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy (Benzinga)
• Neutral Sentiment: Guidance reiterated but with modest gaps vs. consensus: Pfizer reaffirmed FY‑2026 guidance (EPS $2.80–3.00; revenue $59.5B–62.5B), roughly in line but the EPS range is slightly conservative versus consensus, leaving limited upside in near‑term estimates. Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance (BusinessWire)
• Negative Sentiment: Higher R&D and expense pressure: Increased R&D spending weighed on profit, producing lower adjusted margins vs. the prior year and signaling near‑term profit pressure as the company invests in pipeline. Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending (WSJ)
• Negative Sentiment: Mixed market reaction and skepticism: Some analysts call the quarter “mild” — beats were offset by conservative guidance and margin pressures, so the report may not satisfy investors focused on near‑term sales acceleration. Why Pfizer’s ‘Mild’ First-Quarter Report Likely Won’t Satisfy Skeptics (Investors.com)

Analyst Ratings Changes

Several brokerages have issued reports on PFE. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. Morgan Stanley lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. BMO Capital Markets restated an “outperform” rating and set a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. Finally, HSBC upped their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $28.74.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.